Exchange Traded Concepts’s Protagonist Therapeutics PTGX Stock Holding History

Exchange Traded Concepts’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.54M	Sell	18,035 -6,089	-25%	-$868K	0.01%	671
2026 Q2	$2.96M	Buy	24,124 +351	+1%	+$36.7K	0.01%	595
2026 Q1	$2.51M	Sell	23,773 -11,266	-32%	-$998K	0.02%	546
2025 Q4	$3.06M	Buy	35,039 +1,487	+4%	+$122K	0.02%	500
2025 Q3	$2.23M	Sell	33,552 -13,839	-29%	-$787K	0.02%	541
2025 Q2	$2.62M	Buy	47,391 +19,999	+73%	+$960K	0.03%	432
2025 Q1	$1.32M	Buy	27,392 +26,367	+2,572%	+$1.1M	0.02%	471
2024 Q4	$39.6K	Buy	1,025 +64	+7%	+$2.79K	﹤0.01%	1239
2024 Q3	$43.2K	Buy	+961	New	+$38.8K	﹤0.01%	1209

Other funds holding PTGX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

Exchange Traded Concepts's PTGX Position: Q3 2026 in Review

Exchange Traded Concepts reduced its Protagonist Therapeutics (PTGX) stake by 25% in Q3 2026, selling an estimated $868K and leaving 18,035 shares worth $2.54M. The position accounts for 0.01% of the portfolio, ranked #671.

Exchange Traded Concepts first reported a position in PTGX in Q3 2024 and has held it in 9 quarters since. The position peaked at $3.06M in Q4 2025. 294 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

Exchange Traded Concepts held 18,035 shares of Protagonist Therapeutics worth $2.54M as of Q3 2026.
Exchange Traded Concepts sold 6,089 Protagonist Therapeutics shares in Q3 2026, an estimated $868K.
Protagonist Therapeutics made up 0.01% of Exchange Traded Concepts's portfolio in Q3 2026, its #671 holding.
Exchange Traded Concepts first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 9 quarters since.
Exchange Traded Concepts's Protagonist Therapeutics position peaked at $3.06M in Q4 2025.
294 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Exchange Traded Concepts's 13F filing for Q3 2026, filed 28 Oct 2026.